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International Reciprocity: If a Drug Is Good 
Enough for Great Britain, It Should Be 
Good Enough for the United States 
Nicole C. Perez* 
The pharmaceutical industry is one of the largest, and most 
lucrative, industries in the world, worth about one trillion U.S. 
dollars. Specifically, the United States accounts for more than 
one-third of the global pharmaceutical market with about 340 
million dollars in sales. Not only is the pharmaceutical industry 
one of the biggest industries profit-wise, but it is also an industry 
that affects almost every single person in the world. In a nation 
where healthcare issues are always on the rise, ensuring that 
American citizens benefit from pharmacology is essential to 
improving the nation’s healthcare system. The Food and Drug 
Administration (FDA) is responsible for protecting the public’s 
health by assuring its consumers that the pharmaceutical drugs 
approved in the United States are both safe and effective. 
However, with great responsibility, great problems are sure to 
follow. 
The FDA’s approval process for pharmaceutical drugs is highly 
stringent, costly, and lengthy. While it makes sense to have a 
stringent approval process for pharmaceutical drugs, the cost and 
duration of the process outweigh the benefits that the FDA is 
trying to achieve. The FDA’s stringent approval process refuses 
to allow U.S. consumers access to potentially life-saving 
medicines that have already been approved in other countries, 
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such as Great Britain, whose pharmaceutical regulatory system is 
most similar to that of the United States than any other country. 
By enacting an international reciprocity agreement that allows 
the U.S. to automatically approve drugs that have been approved 
in similar countries, the cost and duration of the FDA’s drug 
approval process would substantially decrease, which could 
potentially save millions of lives. 
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I. INTRODUCTION 
The big, bad, pharmaceutical industry: one of the largest, and most 
lucrative, industries in the world.  With a net worth of about one trillion 
U.S. dollars, the global pharmaceutical industry is responsible for the 
development, production, and marketing of medications around the 
world.1 Specifically, the United States is responsible for the largest portion 
of the global market, generating more than forty percent of the global 
revenue.2 However, despite generating the largest pharmaceutical market 
in the world,3 the pharmaceutical industry in the United States is certainly 
not free of criticism. 
The Food and Drug Administration (FDA) is responsible for 
protecting the public’s health by assuring the safety and efficacy of 
pharmaceutical drugs in the United States.4 However, the process through 
which the FDA regulates such drugs is highly stringent, costly, and 
lengthy.5 The FDA justifies its lengthy and expensive process by 
exercising a “better safe than sorry” attitude. However, critics attack the 
FDA’s over-cautious approval process because it refuses to allow access 
to potentially life-saving medicines that have already been approved in 
other countries, such as Great Britain.6 The regulatory system of Great 
                                                                                                             
1 Statistics and Facts About the Pharmaceutical Industry Worldwide, STATISTA, 
http://www.statista.com/topics/1764/global-pharmaceutical-industry/ (last visited Jan. 16, 
2016). 
2 Id. 
3 Id. 
4 About FDA: What We Do, U.S. FOOD AND DRUG ADMINISTRATION, 
http://www.fda.gov/AboutFDA/WhatWeDo/default.htm (last updated Dec. 7, 2015). 
5 Julie C. Relihan, Note, Expediting FDA Approval of AIDS Drugs: An International 
Approach, 13 B.U. INT’L L.J. 229, 230 (1995). 
6 Id. at 231. 
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Britain is most similar to that of the United States than any other country.7  
Therefore, choosing to automatically approve drugs in the United States 
that have already been approved in Great Britain seems like a no-brainer.  
Nevertheless, the United States has yet to approve such a system. 
Although there is no international agreement in place, there have been 
efforts to harmonize with other countries in the past.  In 1991, the United 
States President’s Council of Competitiveness (President’s Council) 
proposed a series of procedures and reform measures intended to 
accelerate the FDA approval of new drugs.8 The President’s Council 
proposed that the FDA give automatic approval to drugs that have already 
been approved by foreign countries that have a reciprocity agreement with 
the United States.9 The proposal emphasized that only those countries that 
have very similar standards to the FDA would be accepted and negotiated 
on a country-by-country basis.10 However, this agreement has, of course, 
not yet happened. 
Due to the stringent standards of the FDA, it is difficult for the United 
States to enter into any sort of reciprocity agreement. Thus, this comment 
will address why a reciprocity agreement allowing the automatic approval 
in the United States of drugs already approved in Great Britain would be 
beneficial. Furthermore, this comment will also address how adopting 
some aspects of Great Britain’s drug regulation process would minimize 
many of the FDA’s harshest criticisms. Part II of this comment will 
address the history of the FDA and its current drug approval process, as 
well as common criticisms of the FDA approval process. Part III of this 
comment will address the drug regulation and approval process in Great 
Britain. Part IV of this comment will compare the regulations and approval 
process between the United States and Great Britain. Finally, part V of this 
comment will address the benefits of automatically approving drugs from 
Great Britain in the United States. 
                                                                                                             
7 Rosemary P. Wall, International Trends in New Drug Approval Regulation: The 
Impact On Pharmaceutical Innovation, 10 RUTGERS COMPUTER & TECH. L.J. 317, 324 
(1984). 
8 Relihan, supra note 5, at 256. 
9 Amelia A. Esber, Note, Curing the Drug Lag: A Proposal for International 
Harmonization of Pharmaceutical Approval, 31 ARIZ. J. INT’L & COMP. L. 125, 147 (2014). 
10 Id. 
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II. THE REGULATION AND APPROVAL PROCESS OF THE 
FDA 
A. History 
1. The Pure Food and Drugs Act of 1906 
Prior to 1906, there was an influx of counterfeit and contaminated drug 
materials entering the United States from overseas.11 It was not until after 
the Civil War, when interstate commerce began expanding significantly, 
that the United States realized it needed to create a federal rule regulating 
the pharmaceuticals entering the country.12 Subsequently, Congress 
passed the Pure Food and Drugs Act of 1906.13 The purpose of the 1906 
Act was to protect consumers by prohibiting the adulteration and 
misbranding of pharmaceuticals by their manufacturers.14 However, the 
1906 Act suffered a setback when the Supreme Court of the United States 
held that “the law did not prohibit false health claims, only false statements 
about the identity or ingredients of drugs.”15 Therefore, in essence, a 
manufacturer could lie about the therapeutic claims of a drug without any 
repercussions.  As a result, Congress amended the 1906 Act to include the 
prohibition of false and fraudulent label claims of therapeutic 
effectiveness.16  Although this was a genuine attempt to cure the loophole 
of the 1906 Act, the language of the Amendment required that the 
promoter of the pharmaceutical had “deliberately lied to defraud the 
public,” which was almost impossible to prove.17  Therefore, although the 
Pure Food and Drugs Act of 1906 was a noble start to regulating 
pharmaceuticals in the United States, it was clear that more aggressive 
reform efforts were needed in order to protect consumers. 
                                                                                                             
11 Wallace F. Janssen, Outline of the History of U.S. Drug Regulation and Labeling, 36 
FOOD DRUG COSM. L.J. 420, 423 (1981). 
12 Id. at 425. 
13 Pure Food and Drugs Act of 1906, Pub. L. No. 59-384, §§ 1-13, 34 Stat. 768, (1906), 
repealed by Federal Food, Drug and Cosmetic Act of 1938, 52 Stat. 1040, 1059 (codified 
as amended at 21 U.S.C. §§ 301-99f (2012)). 
14 Janssen, supra note 11, at 427.  
15 Id. 
16 Id. at 428. In 1912, Congress passed the Sherley Amendment, which prohibited the 
fraudulent claims of therapeutic effectiveness of pharmaceuticals. 
17 Id. 
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2. The Food, Drug and Cosmetic Act of 1938 
In 1937, tragedy struck when the drug “Elixir Sulfanilamide” was 
responsible for the deaths of more than 100 people in 15 different states.18  
Sulfanilamade was a drug used to treat streptococcal infections, and it was 
proven to safely and effectively cure the infections in both tablet, and 
powder, form.19 However, the problems with the drug arose when a 
Tennessee Pharmaceutical company reported a demand for the drug in 
liquid form.20 As a result, the pharmaceutical company’s chief chemist and 
pharmacist created the liquid form of the drug by mixing different 
chemicals, and distributed it all over the country.21 The problem, however, 
was that the drug was not tested for toxicity because at that time, there was 
no food or drug law that required safety studies be done on new drugs.22 
Following the tragic deaths of innocent consumers, Congress enacted 
The Food, Drug and Cosmetic Act of 1938. The 1938 Act responded to 
the Elixir tragedy by requiring that a pharmaceutical company seeking to 
market its drug to the public must first file an application for approval of 
the new drug.23 Once the FDA received the new drug application, it had 
the option of testing the safety of the drug on human subjects.24  If the 
FDA did not approve, reject, or request additional data from the 
pharmaceutical company within sixty days, then such failure to respond 
would lead to automatic approval of the drug.25 By requiring this extra step 
in the application process, the FDA’s main concern was preventing 
another Elixir tragedy by ensuring that new pharmaceuticals were safe to 
pass on to consumers. 
3. The Drug Amendments of 1962 
In the 1960s, another pharmaceutical tragedy occurred, but this time it 
was in Europe. The tragedy struck when the drug “thalidomide” was found 
to cause birth defects in babies born by mothers who had taken the 
experimental drug, as a part of a clinical trial, during their pregnancies.26  
As a result, Congress passed the 1962 Amendments, which required that a 
                                                                                                             
18 Carol Ballentine, Taste of Raspberries, Taste of Death: The 1937 Elixir Sulfanilamide 
Incident, FDA CONSUMER MAG., June 1981, at 1. 
19 Id. 
20 Id. 
21 Id. 
22 Id. 
23 Food, Drug and Cosmetic Act of 1938, 21 U.S.C § 355 (2012). 
24 Id. 
25 Summary of NDA Approvals & Receipts, 1938 to the Present, U.S. FOOD AND DRUG 
ADMINISTRATION, http://www.fda.gov/aboutfda/whatwedo/history/productregulation/sum
maryofndaapprovalsreceipts1938tothepresent/default.htm, (last updated Jan. 18, 2013). 
26 Esber, supra note 9, at 128. 
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new drug undergo a series of clinical tests to not only prove the safety of 
the drug, but also to verify the effectiveness of the drug.27 During  clinical 
testing, the FDA has the right to stop any testing, or order changes to the 
testing, if the drug is deemed unsafe or ineffective.28 The major change 
created by the 1962 Amendments is the requirement of proof of efficacy, 
in addition to the proof of safety requirement. 
B. New Drug Application: The Approval Process of the FDA 
The Food, Drug and Cosmetic Act of 1938 provided for two different 
routes of approval for drug marketing in the United States. The first route 
is that the drug must be one that is exempted from the 1938 Act by the 
1962 Amendments.29 The second route of approval, which is the route that 
this comment will be focusing on, is that the FDA must approve the drug 
under the New Drug Application (NDA) procedures.30 Under the NDA 
approval process, there are four stages that must be accomplished before 
a decision can be rendered on whether or not to approve the drug. The four 
stages of the NDA approval process are the following: (1) pre-clinical 
testing; (2) investigational new drug stage; (3) NDA stage; and (4) post-
marketing surveillance. 
1. First Stage: Pre-Clinical Testing 
The first step of the NDA approval process is pre-clinical testing, 
which lasts about eighteen months.31 During this stage, the drug sponsor 
must conduct clinical investigations to show that the drug is reasonably 
safe by performing the drug testing and analysis on animals.32 The main 
purpose of these pre-clinical tests is to ensure that the drug is reasonably 
safe for human beings before commencing the human preliminary clinical 
investigations.33 
2. Second Stage: Investigational New Drug Application 
After the pre-clinical testing, if the drug sponsor concludes that the 
drug is shown to be both safe and effective for humans, then the sponsor 
must file an Investigational New Drug (IND) Application.34 In the IND 
                                                                                                             
27 21 U.S.C. § 355(d). 
28 Esber, supra note 9, at 129. 
29 David W. Jordan, Note, International Regulatory Harmonization: A New Era in 
Prescription Drug Approval, 25 VAND. J. TRANSNAT’L L. 471, 478 (1993). 
30 Id. 
31 Id. at 479. 
32 21 C.F.R. § 312.23(a)(8) (2016). 
33 Jordan, supra note 29, at 479. 
34 Esber, supra note 9, at 130. 
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application, the drug sponsor must include the results of the pre-clinical 
testing, including both the animal toxicology, and the human testing 
studies conducted.35 After submitting the IND to the FDA, the drug 
sponsor must wait thirty days while the FDA reviews the IND.36 If the 
FDA responds favorably within thirty days, or does not respond at all, then 
the drug sponsor is permitted to begin clinical testing.37 However, the FDA 
has the option to place the IND on “clinical hold” within the thirty days, 
which would prevent further commencement of that specific IND due to 
possible concerns regarding the drug.38 
In addition, there are three phases of clinical investigations that are 
conducted during the IND stage. Phase I begins with initial introduction 
testing of the new drug on about twenty to eighty human subjects, whom 
consist of both patients and volunteers.39 The studies conducted during this 
phase are designed to determine “the metabolism and pharmacologic 
actions of the drug in humans, the side effects associated with increasing 
doses, and if possible, to gain early evidence on effectiveness.”40 
Phase II begins to specify the broad testing from Phase I. The studies 
in Phase II are conducted to “evaluate the effectiveness of the drug for a 
particular indication or indications in patients with the disease or 
condition,” and to “determine the common short-term side effects and 
risks associated with the drug.”41 Here, the primary consideration is the 
effectiveness of the drug on human subjects, whom have the specific 
disease that the drug intends to treat.42 Phase II involves well controlled, 
and closely monitored studies, on no more than several hundred human 
subjects within an average of about eighteen months.43 
Finally, Phase III is the longest and most extensive phase of clinical 
testing, lasting about three years on average.44 The trials in Phase III are 
conducted only after preliminary evidence from both Phases I and II show 
that the drug has been effective.45 The studies conducted in Phase III are 
“intended to gather the additional information about effectiveness and 
safety that is needed to evaluate the overall benefit-risk relationship of the 
drug and to provide an adequate basis for physician labeling.”46 Phase III 
                                                                                                             
35 21 C.F.R. § 312.22 (c). 
36 Id. § 312.40(b)(1). 
37 Id. 
38 Id. 
39 Id. § 312.21(a)(1). 
40 Id. § 312.21(b). 
41 Id. 
42 Id. (emphasis added). 
43 Id.; see also Jordan, supra note 29, at 480. 
44 Jordan, supra note 29, at 480. 
45 21 C.F.R. § 312.21(c) (emphasis added). 
46 Id. 
2016-2017] INTERNATIONAL RECIPROCITY 177 
	
studies have the most subjects of the three phases, ranging from about 
several hundred to several thousand subjects.47 
It is important to note that, during the IND stage, the FDA may 
terminate clinical testing at any phase of the IND stage if it is found that 
there are deficiencies in the IND, or in the actual conduct of an 
investigation under an IND.48 Furthermore, the drug sponsor itself may be 
required to terminate the investigation if any substantial doubt arises as to 
the safety and efficacy of the drug.49 
3. Third Stage: New Drug Application 
If the three phases of the IND stage are successfully completed, the 
drug sponsor must then file a New Drug Application (NDA) with the 
FDA.50 The NDA “has become the principal regulatory device for the 
control of drugs in the United States.”51 The goals of the NDA are to 
provide enough information to permit the FDA to find whether the drug is 
safe and effective in its proposed uses, whether the benefits of the drug 
outweighs the risks, whether the drug’s proposed labeling is appropriate 
in its information, and whether the methods used in manufacturing and 
controlling the drug maintain the drug’s quality adequately in order to 
preserve the drug’s identity, strength, quality, and purity.52  The NDA is 
basically a compilation of all the information from the IND phase, and in 
essence, tells the drug’s “whole story.”53 
After an NDA has been filed, the FDA has six months to approve or 
reject the NDA.54 If the FDA approves the NDA, the drug sponsor must 
then maintain records of data relating to clinical experience and other data 
or information received or obtained with respect to the drug.55 
4. Fourth Stage: Post-Market Surveillance 
Finally, the fourth and final stage of the approval process is post-
marketing surveillance. Although the Food, Drug and Cosmetic Act of 
1938 does not specifically require drug sponsors to conduct post-
                                                                                                             
47 Id. 
48 Id. § 312.44(a); see also id. § 312.44(b) (listing specific grounds for termination of 
the IND). 
49 21 C.F.R. § 312.44(b)(vii). 
50 21 U.S.C. § 355(a)-(b). 
51 Jordan, supra note 29, at 481. 
52 New Drug Application (NDA), U.S. FOOD AND DRUG ADMINISTRATION, http://www.
fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/App
rovalApplications/NewDrugApplicationNDA/ (last updated Feb. 3, 2015). 
53 Id. 
54 21 U.S.C. § 355(c). 
55 Id. § 355(k). 
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marketing surveillance, it has become routine through agency practice.56  
The goal of post-marketing surveillance is find out more information about 
a drug’s safety and efficacy by monitoring instances of adverse or 
uncommon reactions to the drug.57 The post-marketing surveillance stage 
is extremely important because it detects any unknown side effects caused 
by the drug that are not detected in the previous stages.58 A major issue 
concerning post-marketing surveillance is that the FDA may lack the 
money and/or staff necessary in order to provide efficient and effective 
surveillance of new drugs.59 As a result, the FDA made it “mandatory”60 
for drug companies to report when drugs show adverse effects, however, 
such reporting is often too late, or never occurs at all.61 
C. Generic Drug Approval Process 
When a drug has successfully completed the NDA approval process, 
it is approved and marketed as a “brand name” drug. A brand name drug 
is “the first to contain a particular active ingredient or ingredients to 
receive FDA approval for a specified use.”62 In order to protect a drug 
company’s exclusivity of its newly approved drug, the company develops 
the drug under a patent, which allows the company the sole right to sell 
the drug while the patent is in effect.63 However, once the patent expires, 
generic drug companies can compete with the brand name drug by entering 
their generic version of the drug into the market.64 
1. What is a Generic Drug? 
A generic drug is a copy of a brand name drug, which can enter the 
market once the brand name drug’s patent, or period of exclusivity, has 
expired.65 Generic drugs play a large role in competing with brand name 
drugs because generic drugs are often priced much lower than brand name 
drugs, which is mainly due to lower development costs.66 Due to their 
                                                                                                             
56 Jordan, supra note 29, at 483. 
57 Esber, supra note 9, at 131. 
58 Id. at 131-32; see also Richard Deyo, Gaps, Tensions, and Conflicts in the FDA 
Approval Process: Implications for Clinical Practice, 17 J. AM. BD. FAM. MED. 142, 142-
49 (2004): Some experts claim that approximately half of all new drugs have unknown side 
effects that are not discovered until the post-marketing surveillance stage. 
59 Deyo, supra note 58, at 142-49. 
60 The author of this Note added quotations for emphasis. 
61 Deyo, supra note 59, at 142-49. 
62 Justina A. Molzon, The Generic Drug Approval Process, 5 J. PHARMACY & L. 275, 
275 (1996). 
63 Id. 
64 Id. 
65 Id. 
66 Id. 
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lower prices, many believe that generic drugs are inferior to brand name 
drugs, and are therefore not as effective.67 This belief, however, is 
unfounded given that generic drugs contain the exact same active 
ingredients as the brand name drug, and they must have the same safety 
and efficacy standards as the brand name drug as well.68 Although generic 
drugs may differ in inactive ingredients, such as capsules versus tablets, 
they are still equally comparable in regard to dosage form, strength, route 
of administration, quality, performance, and intended use.69 
2. History of Generic Drug Regulation 
In 1984, Congress passed the Waxman-Hatch Act, which is largely 
responsible for the increase of generic drugs available on the market 
today.70 The Act was passed in order to “achieve objectives related to 
competitive and commercial forces in the regulated drug industry.”71 The 
Act represented an effort to create a balance between the competing forces 
in the pharmaceutical industry: generic drugs and brand name drugs.72 The 
Act also extended the abbreviated new drug application (ANDA) process, 
which allowed for generic versions of brand name drugs to enter the 
market when the brand name patent or period of exclusivity expired.73 The 
Act simplified the ANDA approval process by “eliminating the need for 
sponsors to repeat duplicative, unnecessary, expensive and ethically 
questionable clinical and animal research to demonstrate the safety and 
efficacy of the drug product.”74 The reasoning behind this change was that 
it was recognized that the safety and efficacy of the drug had been 
adequately and sufficiently demonstrated by the studies conducted by the 
brand name drug manufacturer.75 Furthermore, the fact that the brand 
name drug had already been accepted by the medical community and had 
already been in widespread use, showed that the drug was acceptable, and 
there was no need to conduct double testing on the same product.76 
3. The ANDA Approval Process 
The application for generic drugs is called an “abbreviated new drug 
application” because the approval process does not need to duplicate the 
                                                                                                             
67 Id. 
68 Id. 
69 Id. at 276. 
70 Id. 
71 Id. 
72 Id. 
73 Id. 
74 Id. 
75 Id. 
76 Id. 
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safety and efficacy trials that were previously conducted for the brand 
name drug; hence the term “abbreviated.”77 An ANDA is submitted to 
propose a generic drug that is already the “same” as a previously FDA 
approved drug.78 The generic drug manufacturer must submit enough 
information to show that the generic drug described in the ANDA is the 
same as the previously approved brand name drug in regards to its active 
ingredient, dosage form, strength, and route of administration.79  
Furthermore, the generic manufacturer must also comply with the same 
FDA requirements that were imposed on the brand name product.80 
Therefore, the generic manufacturer must meet the same standards for 
manufacturing practices, identity, strength, quality, and purity.81 
The only difference permitted between a generic drug and a brand 
name drug is the contents of the label of the generic drug.82 The labeling 
submitted by the generic drug must contain the same information as the 
brand name drug, except for the modifications of the generic drug due to 
the brand name drug’s patent of exclusivity.83 The generic drug’s labeling 
can also differ in regards to tablet shape, color, capsule, etc.84 
4. Bioequivalence: How Alike Are They? 
In addition to all the gathered information regarding the chemistry, 
manufacturing, control, and labeling of the generic drug, the generic 
manufacturer must also include information about the drug’s 
bioequivalence on the ANDA.85 The bioequivalence of the drug is 
demonstrated by showing that the generic drug delivers the same amount 
of active ingredient, at the same rate and extent, as the brand name drug.86  
In order to reach such a conclusion, the generic manufacturer must conduct 
a bioequivalence study.87 
Bioequivalence studies are conducted at a fraction of the cost of a 
brand name clinical study, and usually involve about eighteen to twenty-
four human volunteers.88 Typically, in bioequivalence studies, each 
volunteer receives both the brand name drug, and the test drug, because 
                                                                                                             
77 Id. at 277. 
78 Id. 
79 Id. 
80 Id. 
81 Id. 
82 Id. 
83 Id. 
84 Id. 
85 Id. 
86 Id. 
87 Id. 
88 Id. 
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blood levels of the drug, even from the same product, will vary in different 
people.89 For a generic product to be found bioequivalent to the brand 
name drug, the generic product’s absorption to the blood can only differ 
from the brand name’s absorption by less than ten percent.90 Therefore, 
due to the various regulations and strict  FDA requirements, there is no 
reason to believe that a generic drug is less effective than a brand name 
drug. 
D. Major Criticisms of the FDA Approval Process in the United 
States 
1. The Drug Lag 
The most common criticism of the FDA’s pharmaceutical approval 
process is the drug lag. Since the passage of the 1962 Amendments to the 
Food, Drug and Cosmetic Act of 1938, the time required to gain approval 
for new drugs has risen substantially.91 Before the 1962 Amendments, it 
took about three to four years for an NDA to become approved, and enter 
the market.92 Today, it takes about eleven to fourteen years for a new drug 
to enter the marketplace after approval, which is more than triple the 
amount of time of approval before the enactment of 1962 Amendments.93  
Many critics agree that the 1962 Amendments have largely contributed to 
the drug lag because the Amendments added the stringent efficacy 
requirement to the already strict safety requirement of the FDA.94 
Arguably the biggest problem that has arisen as a result of the drug lag 
is the increase in deaths of Americans who are waiting on potentially life-
saving drugs to be accepted by the United States.  The bacterial meningitis 
outbreak, which occurred at Princeton University in 2013, is a prime 
example.  Bacterial meningitis is a deadly bacteria, which causes swelling 
of the membranes covering the brain and spinal cord.95 Once infected, 
those whom are lucky enough to survive are often left with permanent 
disabilities such as paralysis and mental disabilities.96 In March 2013, 
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seven cases of bacterial meningitis were diagnosed at Princeton 
University. There is no approved vaccine in the United States for this 
disease; however, Europe, Australia, and Canada all have an approved 
vaccine known as Bexsero.97 As a result, The Centers for Disease Control 
and Prevention (CDC) were able to lobby the FDA into allowing “special 
and unusual permission” to import Bexsero to the United States, but only 
for this specific instance.98 Princeton was then able to administer the 
vaccine to any student who wanted it.99 
The point of grave concern in this situation is that the bacterial 
meningitis vaccine, Bexsero, is in clinical trials in the United States, but 
the FDA has slowed the testing and approval process of the vaccine.100  
Even more concerning is the fact that the FDA clinical testing of Bexsero, 
thus far, has in fact confirmed that “the vaccine will help protect against 
the exact strain of bacteria that is causing the outbreak.”101 It has been 
proven that the clinical trial length of new drugs is the main reason as to 
why it takes so long for new drugs to be approved.102 This can be attributed 
to a number of factors, including increased regulatory requirements, the 
need for more study subjects, an increase in difficulty of recruiting 
subjects, and the nature of the disease being investigated.103 However, if 
the FDA had expedited this clinical testing process, knowing that the 
vaccine protects against bacterial meningitis, some of the cases at 
Princeton could have potentially been prevented.  Furthermore, regardless 
of the Princeton outbreak, bacterial meningitis kills approximately five 
hundred people a year in the United States alone.104 Such a statistic alone 
should encourage the FDA to expedite the approval of a potentially life-
saving vaccine. 
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2. Political Power of the FDA 
Like any other business relationship, conflicts often arise between the 
FDA and pharmaceutical companies. However, critics of the FDA argue 
that pharmaceutical companies are hesitant to challenge decisions by the 
FDA in a legal environment based on the fear that the FDA will retaliate 
in the future.105 Critics further argue that the FDA delays its consideration 
of a pharmaceutical company’s new drug if any controversy arises 
between the two during the approval process.106 Therefore, critics contend 
that if the FDA evaluated new drugs solely on their scientific and 
therapeutic merits, then the drug approval process would be much 
quicker.107 
In essence, critics could argue that the FDA is basically a monopoly, 
being the sole approver of pharmaceuticals in the United States. Studies 
show that regulatory agencies, such as the FDA, structure their employees 
to perform their tasks cautiously, usually with excessive caution,108 in 
order to prevent any backlash for approving a drug that may turn out to be 
harmful. Consequently, FDA employees have a “natural bias” to withhold 
new and potentially useful drugs from the market.109 However, critics 
argue that preventing effective new drugs from the public, especially from 
those whom have no other means of treatment, is just as harmful as letting 
potentially harmful drugs slip through the cracks.110 Therefore, critics 
believe that the FDA must restructure the mindset of their employees to 
allow a more efficient drug review process.111 
3. Heavy Costs Associated with Drug Approval 
Similar to the drug lag, the efficacy requirement of the 1962 
Amendments to the Food, Drug and Cosmetic Act of 1938 increased the 
testing requirements for new drug approval.112 As a result, the costs 
associated with drug approval increased in order to meet the new efficacy 
requirement.113 In 2014, it cost an estimated 2.4 billion dollars to develop 
a new drug.114 Due to the astronomical costs of approving new drugs in 
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the United States, evidence has shown that many “orphan drugs,”115 which 
are potentially useful drugs, were not being introduced in the United States 
because the high costs of FDA approval would exceed any potential sales 
revenue of the drug.116 Furthermore, as a result of the lack of useful drugs, 
due to the high costs of FDA approval, many Americans sought treatment 
overseas, or resorted to using black-market drugs from unapproved 
suppliers who were selling the unapproved drugs.117 
Although ANDA’s have much lower development costs compared to 
NDA’s due to its abbreviated application, an ANDA cannot exist without 
an already approved NDA.118 Therefore, if researchers continue to steer 
away from bringing new, helpful drugs into the United States as a result 
of the high development costs, then the United States will be absent of 
both the useful drugs, and its cheaper generic counterpart. 
III. THE DRUG REGULATION AND APPROVAL PROCESS IN 
GREAT BRITAIN 
A. History 
As a result of the previously discussed thalidomide disaster in Great 
Britain,119 the Committee on Safety of Drugs was created in 1963.120 This 
committee later became the Committee on Safety of Medicines (CSM) 
under the regulation of the Medicines Act of 1968.121 The Medicines Act 
provides the legal framework for the control of medicines in the United 
Kingdom, and requires that pharmaceuticals be licensed before being 
allowed in the open market.122 Then, the Medicines Control Agency was 
created in 1989, and merged with the Medical Devices Agency in 2003 to 
become the Medicines and Healthcare Products Regulatory Agency 
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(MHRA).123 The criteria on which the MHRA bases its evaluations consist 
of safety, quality, and efficacy.124 The Commission on Human Medicines 
(CHM), formerly the CSM, provides expert advice to the MHRA in the 
review of all drugs.125 In addition, the MHRA works closely with the 
European regulator, the European Medicines Agency (EMA), whose 
legislation supersedes the MHRA.126 
B. The Drug Approval Process of the MHRA 
Before any medicine can be introduced into the market, a license 
referred to as a “marketing authorization” must be issued by the MHRA.127  
In order to receive this authorization, pharmaceutical companies and 
researchers must apply to the MHRA for permission to test their drugs 
through clinical trials.128 In order to obtain permission to begin a clinical 
trial, the pharmaceutical company must show that it has satisfied the strict 
safety criteria of the MHRA.129 Once the clinical trials are completed, the 
test results establishing how well the medicine works, any side effects, 
details of what the medicine contains, how the medicine works in the body, 
and who it is meant to treat, are sent the MHRA for assessment.130 The 
assessment team of the MHRA is composed of experts from different 
relevant specialties, whom have undergone additional training in medicine 
assessment specifically.131 The duration of the MHRA assessment process 
depends on the type of medicine, the quality of the initial information of 
the medicine supplied by the manufacturer, how much further detail is 
required, and how soon any uncertainties can be resolved.132 During its 
assessment, the MHRA must comply with “strict timeframes and 
performance targets” for the licensing of medicines.133 The pharmaceutical 
company must be able to show the MHRA that the manufacture, 
distribution, and supply of the medicine meet the required safety and 
quality standards of the MHRA.134 Once the MHRA is satisfied that the 
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medicine is both safe and effective, it grants the pharmaceutical company 
the marketing authorization for the medicine.135 
1. Post-Market Surveillance 
In Great Britain, manufacturers are required by law to report to the 
MHRA any important defects that are discovered in their drugs after they 
have been on the market.136 When a medicine is suspected or discovered 
to be faulty, the MHRA immediately works with the manufacturers on “the 
most appropriate and timely action to take,” which may mean completely 
recalling the medicine from the market.137 If an issue arises with a 
medication, but a total recall is unnecessary, the MHRA then issues 
warnings about defective medicines, problems with the medicine, and any 
side effects discovered from the medicine.138 These warnings are sent out 
to healthcare professionals and organizations, and are also publicized 
widely both in print and online, including the MHRA website.139 The 
MHRA prioritizes responding to any possible concerns of new drugs, so 
the MHRA holds the power to prosecute manufacturers for not reporting 
any such concerns.140 
In addition, patients are also permitted, but not required, to report any 
concerns with medicines they are taking through what is known as the 
Yellow Card Scheme.141 The Yellow Card Scheme allows patients to 
report side effects directly, either online or by phone, without having to 
rely on a healthcare professional to do so.142 The Yellow Card Scheme is 
a highly useful tool because the reports go straight to the pharmaceutical 
companies, which allow the companies to make a change in their product 
and be aware of any concerns.143 
Although there have naturally been instances where the MHRA has 
approved drugs that were too dangerous or ineffective to stay on the 
market, the MHRA enforces its immediate withdrawal procedures as soon 
as any serious concern is reported.144 
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IV. AN INTERNATIONAL COMPARISON: THE FDA V. THE 
MHRA 
The drug regulation system in Great Britain is substantially 
comparable to the regulation system in the United States.145 Specifically, 
the regulation in Great Britain is actually more similar to that of the United 
States than any other nation.146 Nevertheless, the two systems differ in 
certain areas, such as the focus of pre- and post-market surveillance, the 
safety and efficacy requirement, and the politics of the regulatory 
agencies.147 
A. Pre-Market v. Post–Market Surveillance 
In Great Britain, the MHRA focuses more on the post-market 
surveillance stage, whereas the FDA in the United States focuses more on 
the pre-market evaluation process.148 The MHRA approval process 
generally requires much less time than that of the FDA because the MHRA 
primarily monitors the safety and efficacy of the drug after the drug has 
obtained approval.149 The FDA, on the other hand, generally requires more 
time during the approval process because it determines the safety and 
efficacy of a drug before the approval is granted.150 As a result, drugs are 
approved an average of two years sooner in Great Britain than in the 
United States.151 The FDA attempts to discover any adverse side effects, 
safety issues, and efficacy issues of a drug during its lengthy and costly 
clinical trial stage.152 However, it has been noted that the MHRA’s 
approach of focusing more on the post-market stage more accurately 
reflects scientific reality: “[W]hile short-term, pre-market tests are well 
designed the reveal frequent side effects, only long-term experience in a 
large, widely varied population is likely to yield rare and perhaps more 
serious reactions, as well as genetic and other long term toxic responses to 
a drug.”153 
Furthermore, the MHRA requires mandatory reporting of adverse 
drug reactions, as well as other studies or new information, regarding the 
newly approved drug.154 The FDA, on the other hand, lacks the legal 
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authority to enforce manufacturers to report such instances.155 In the 
United States, the decision of the manufacturer to report an incident 
regarding a drug is completely subjective, and the FDA can only 
recommend a manufacturer to submit information concerning the new 
drug.156 In addition, when an instance of non-reporting by a manufacturer 
does occur, the FDA rarely seeks assistance from the Department of 
Justice to take legal action against the manufacturer.157 In Great Britain, 
however, the MHRA has the direct legal authority to prosecute 
manufacturers for failing to report any adverse instances relating to a drug 
already out in the market.158 
B. Safety and Efficacy Requirements 
Another major difference between the regulatory system in Great 
Britain and the regulatory system in the United States is the emphasis on 
the safety and efficacy requirements.159 In the United States, the FDA is 
responsible for determining that both the safety and efficacy requirements 
have been met for a new drug.160 In Great Britain, however, the MHRA is 
only primarily concerned with the safety requirement.161 The 
responsibility of determining the therapeutic efficacy of the drug lies in 
the hands of a separate medical advisory committee.162 As a result, patients 
in Great Britain are able to obtain access to new drugs that have not been 
authorized for human use, as long as a physician prescribes the drug for 
therapeutic purposes.163 The MHRA’s focus on safety, rather than 
efficacy, allows new drugs to enter the market quicker because it does not 
require the extensive studies of determining the drug’s efficacy.164 
Therefore, the system in Great Britain is less expensive, and less time 
consuming, than the approval system in the United States.165 
C. Politics 
One final distinction between the regulatory system of the United 
States and the regulatory system of Great Britain is the weight of politics 
within the agencies.  As previously discussed, the MHRA and FDA differ 
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in their responsibilities in regards to the safety and efficacy of drugs.166  
The MHRA, by using a separate advisory committee to determine the 
efficacy of a drug, isolates approval decisions from political, private, and 
commercial influences.167 The FDA, on the other hand, is responsible for 
determining all the requirements of a new drug, without the input or 
assistance of any outside committee.168 By using separate medical 
advisory committees to make such decisions, a manufacturer in Great 
Britain can feel confident that “the submission of additional, persuasive 
scientific data will result in an objective, expeditious, and positive 
evaluation.”169 The FDA, however, being the sole authority for drug 
approval, is subject to undue influence by political pressures, which 
interfere with the fair, scientific evaluation of a new drug.170 Therefore, 
the approval process in Great Britain “may justifiably be viewed as 
scientific, rather than political, because it leaves scientific evaluation of 
new drug uses to the scientists as opposed to vesting this authority in 
bureaucrats far less suited to the task.”171 
V. ADOPTING ASPECTS OF REGULATION FROM GREAT 
BRITAIN: A RATIONAL SOLUTION 
A. Adopting Facets of Great Britain’s Drug Regulation Process 
1. Emphasis on Post-Market Surveillance 
One of the major critiques of the current drug approval process of the 
FDA is the length and cost associated with the process. By focusing 
primarily on the pre-market surveillance stage, the FDA spends more time 
and money trying to determine the safety and efficacy of a drug before it 
enters the market.172 Instead, the FDA should follow the MHRA and focus 
primarily on the post-market surveillance stage, rather than the pre-market 
stage. By doing so, the FDA would eliminate the lengthy and costly 
clinical trial stage, and the post-market surveillance would depict a more 
accurate reality of any adverse side effects resulting from the drug. 
Furthermore, the MHRA requires mandatory reporting of drug 
reactions, as well as other studies or new information regarding the newly 
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approved drug.173 The FDA should adopt this regulation because as of 
now, the FDA has no authority to require any drug manufacturer to report 
any side effects. If the FDA enforced such reporting, it would save time 
and money by no longer being the only authority surveying any side 
effects. In addition, the FDA should adopt the policy of the MHRA that 
allows patients themselves to report any adverse side effects of drugs.174  
By opening up a resource that would allow patients to directly report any 
side effects, the FDA would get a first-hand look at how patients are 
reacting, and what side effects are issues are arising. This would also save 
time by eliminating the need for the patient to wait for their doctor to report 
the side effect, with the possibility of the doctor forgetting to report, or just 
simply deciding not to. In addition, allowing patients to report side effects 
on their own would make them feel more connected to the system, and 
allow them to have more confidence in the medicines they are taking.  
Therefore, it seems logical for the FDA to consider adopting these aspects 
of the MHRA in regards to post-market surveillance. 
2. Emphasis on Safety Rather Than Efficacy 
Another reason the FDA drug approval process is so lengthy and 
costly is the requirement of meeting both the safety and efficacy standard 
of a new drug.175 The MHRA, however, focuses primarily on the safety of 
a drug.176 By focusing primarily on the safety requirement, the MHRA is 
able to get drugs out on the market quicker, which saves money and lives.  
For example, patients are able to use a drug that may not be authorized for 
human use yet, as long as a physician prescribed the drug for therapeutic 
purposes.177 By doing so, patients are able to use potentially live saving 
drugs, regardless of their efficacy for their specific disease, as long as it is 
therapeutically effective. The FDA should adopt this process because it 
would speed up the current drug approval lag, and it would allow patients 
in the United States to obtain quicker access to drugs that may be 
beneficial on a therapeutic level. Therefore, by focusing primarily on 
safety rather than efficacy, the FDA would be able to speed up its lengthy 
approval process, and save money and lives in the meantime. 
3. Eliminate Risk of Political Influence 
In any governmental agency, political influences can largely impact 
any decisions or regulations. The MHRA, however, seeks to resolve that 
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issue by using independent medical advisory committees in determining 
the efficacy of new drugs during the approval process.178 By doing so, the 
MHRA is able to focus solely on the scientific analysis of new drugs, 
rather than make decisions based on political bias. The FDA should work 
towards adopting this policy in order to minimize the large criticism it 
faces regarding political influences. Critics assert that the FDA, being the 
sole authority for drug approval, is easily subject outside political 
pressures, which may interfere with the fair, scientific evaluation of a new 
drug.179 Therefore, in order to make sure that the best and most effective 
drugs are entered into the market, the FDA should enlist in independent 
medical advisory committees in order to ensure that consumers in the 
United States are receiving the best medical care, based purely on a 
scientific analysis. 
B. Automatically Adopting Drugs Already Approved in Great 
Britain 
1. Minimize the Drug Lag 
The drug lag associated with the approval process of the FDA can be 
greatly improved by adopting drugs that are already approved by the 
MHRA. The drug lag in the United States is concerning because the slower 
that drugs are approved, the slower they are available to consumers who 
would greatly benefit from them. The FDA and the MHRA both have a 
primary requirement of safety in regards to new drugs, so the FDA need 
not worry about automatically approving drugs that were inherently 
unsafe. By approving drugs in the United States that have already been 
approved in Great Britain, the FDA will prosper because it will be able to 
use that time, which would have otherwise been used for evaluating that 
same drug, and invest that time into another drug that has not been 
approved elsewhere. Therefore, the FDA would relieve itself of doing 
double the work, and would be able to move on to evaluating other drugs 
quicker. 
Furthermore, allowing automatic approval of drugs in Great Britain 
would prevent another disaster from occurring, like that of the meningitis 
outbreak in 2013, where the vaccine was approved in Great Britain, but 
not yet in the United States due to delayed clinical trials.180 If such a system 
of automatic approval was in force during the outbreak, it could have 
prevented the lives lost as a result of the delay in the approval of the 
vaccine. The clinical trial stage of new drugs is the lengthiest stage in the 
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approval process, which attributes mostly to the drug lag.181 Therefore, if 
the FDA can eliminate this lengthy process for drugs that have already 
been approved in Great Britain, the drug lag would decrease significantly, 
and many lives would be saved. 
In addition, minimizing the drug lag would consequently decrease the 
costs associated with drug approval in the United States significantly. By 
adopting approved drugs from Great Britain in the United States, both the 
FDA and drug manufacturers would save millions of dollars in research 
and manpower. Instead of spending money conducting clinical trials on a 
drug that is already widely used in Great Britain, drug manufacturers can 
use that money towards researching new drugs that are not yet available 
anywhere else. 
2. Eliminate Political Influences 
By automatically adopting drugs that have already been approved in 
Great Britain, the United States can prevent the FDA from being 
influenced by outside political pressures or biases in the approval process.  
Unlike the FDA, the drugs that are approved in Great Britain go through a 
medical advisory committee, independent of the MHRA, to prevent any 
political influence.182 A main concern of the FDA in the United States is 
that there may be political bias as to whether or not a drug should be 
approved.183 If the United States agreed to adopt already approved drugs 
in Great Britain, however, then the FDA would not be the sole authority 
as to whether or not a drug is approved. This would allow the drug 
manufacturers to feel more comfortable when presenting their new drug 
to the FDA because if the FDA showed any bias, the drug manufacturer 
could leave to Great Britain, therefore taking business away from the FDA.  
As a result, having another agency that introduces new drugs into the 
United States can intimidate the FDA into making sure that a fair, 
unbiased, and purely scientific analysis is conducted on any new drugs. 
In addition, approving drugs in the United States that are already 
approved in Great Britain would also prevent drug manufacturers from 
increasing their prices. By adopting drugs already approved in Great 
Britain, drug manufacturers would be unable to jack up their prices 
because they would not be the only providers of that drug. As a result, the 
consumers would not be forced in to overpaying for a drug, just because 
there is only one manufacturer of that drug in the United States.  Therefore, 
automatic approval would prevent drug manufacturers from benefitting off 
of their monopolization of their drug. 
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3. FDA’s Safety Concerns Are Minimal 
The FDA asserts that it keeps up its stringent approval process in order 
to ensure that the drugs entering the market are both safe and effective.  
However, the approval process in Great Britain has almost the same 
requirements as the FDA, with additional safety provisions.  Both the FDA 
and the MHRA focus on the safety and efficacy of new drugs, although 
the MHRA focuses primarily on the safety requirement. The safety and 
efficacy of new drugs is the most important factor throughout the approval 
process, so the fact that both agencies rely on those requirements is what 
matters the most. It has already been shown that the regulatory system of 
Great Britain is most similar to that of the United States than any other 
country. Therefore, there should be little apprehension in choosing to 
automatically approve drugs in the United States that have already been 
approved in Great Britain. 
Furthermore, implementing international reciprocity for 
pharmaceuticals can arguably be synonymous to the generic drug approval 
process here in the United States. By using the approval process used for 
ANDAs, the FDA can treat drugs that have been approved in other 
countries as generic drugs, which would bypass the whole new drug 
analysis. As a result, the drug lag for that specific drug would be reduced 
significantly, and the costs for approving the new drug would also be 
substantially lower. This way, the FDA is ensured that the drug is safe and 
effective for its consumers, and it also bypasses the time and money it 
takes to approve a brand new drug. As a result, the FDA will still feel like 
an authoritative figure by having the drug undergo their own FDA process, 
while ultimately benefitting the consumers and the people who need these 
drugs in order to survive. Understandably, it can be intimidating for the 
FDA to automatically approve drugs from foreign nations, therefore 
simply analyzing the new drugs under the ANDA system can make 
everyone happy. 
VI. CONCLUSION 
While it is true that no regulatory system or agency can be truly 
perfect, there are certainly things that can be done in order to make 
improvements. The FDA struggles to maintain a proficient approval 
process for new drugs in the United States. By automatically approving 
drugs that have already been approved in Great Britain, the United States 
can minimize some of the criticisms of the FDA, and have the opportunity 
to save money, time, and most importantly, lives. 
 
